Literature DB >> 10628380

The effect of various types of splenectomy on the development of B-16 melanoma in mice.

C Fotiadis1, G Zografos, K Aronis, T G Troupis, V G Gorgoulis, M N Sechas, G Skalkeas.   

Abstract

260 CB57BL/J6 mice were used in an experimental protocol designed to investigate the effects of 4 different varieties of splenectomy on the growth rate of subcutaneously implanted GB-16 melanoma. In addition, the mean and absolute survival of the mice, the histopathology of the tumour and the effects of the same procedures on the immunological status of the tumour-bearing animals as assessed by serum IgG levels and immunoelectrophoresis were determined. The effects of the timing of the splenectomy and the removal of the primary tumour after splenectomy on the above parameters were also annotated. The following were found: First, splenectomy performed 1 week after B-16 melanoma tumour implantation in mice i.e. in the early period of oncogenesis, lengthened the survival of the grafted experiments, delayed tumour growth, reduced the "activity" of the tumour and caused pseudoencapsulation of the tumour by fibrous tissue. It increased, but not by a statistically significant degree (p > 0.05), the circulating levels of the IgG immunoglobulin. Second, splenectomy performed 4 weeks prior to grafting of the same tumour did not affect the circulating IgG levels, nor did it prolong survival; however, it reduced the rate of tumour growth and pseudoencapsulation of the tumour was observed. Third, splenectomy at the early stages of oncogenesis in combination with surgical removal of the primary tumour increased absolute and mean survival, delayed the tumour growth rate, increased the time to relapse and reduced the "activity" of the pseudocapsulated tumour.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10628380

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.

Authors:  Robin Rajan; Manoj K Sabnani; Vikram Mavinkurve; Hilary Shmeeda; Hossein Mansouri; Sandrine Bonkoungou; Alexander D Le; Laurence M Wood; Alberto A Gabizon; Ninh M La-Beck
Journal:  J Control Release       Date:  2017-12-23       Impact factor: 9.776

2.  Spleen-dependent turnover of CD11b peripheral blood B lymphocytes in bovine leukemia virus-infected sheep.

Authors:  Arnaud Florins; Nicolas Gillet; Becca Asquith; Christophe Debacq; Geneviève Jean; Isabelle Schwartz-Cornil; Michel Bonneau; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

3.  SAR131675, a VEGRF3 Inhibitor, Modulates the Immune Response and Reduces the Growth of Colorectal Cancer Liver Metastasis.

Authors:  Katrina A Walsh; Georgios Kastrappis; Theodora Fifis; Rita Paolini; Christopher Christophi; Marcos V Perini
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

4.  Earlier onset of delta-retrovirus-induced leukemia after splenectomy.

Authors:  Arnaud Florins; Michal Reichert; Becca Asquith; Amel-Baya Bouzar; Geneviève Jean; Carole François; Agnieszka Jasik; Arsène Burny; Richard Kettmann; Luc Willems
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

Review 5.  Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research.

Authors:  Enrico Radaelli; Sara F Santagostino; Rani S Sellers; Cory F Brayton
Journal:  ILAR J       Date:  2018-12-31

6.  Tumor-host signaling interaction reveals a systemic, age-dependent splenic immune influence on tumor development.

Authors:  Afshin Beheshti; Justin Wage; J Tyson McDonald; Clare Lamont; Michael Peluso; Philip Hahnfeldt; Lynn Hlatky
Journal:  Oncotarget       Date:  2015-11-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.